Myriad Genetics vs QuidelOrtho
MYGN and QDEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MYGN and QDEL compare
QuidelOrtho is the larger company, worth 1.5 times as much as Myriad Genetics ($909M against $607M).
QuidelOrtho grew revenue faster over the last twelve months (−2.5% versus −3.2% for Myriad Genetics).
Myriad Genetics keeps more of each dollar of sales as profit, with a net margin of −14.0% compared with −39.2% at QuidelOrtho.
Myriad Genetics scores higher on the StockData Score (8 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MYGN | QDEL |
|---|---|---|
| Size and price | ||
| Market cap | $607M | $909M |
| Share price | $6.35 | $13.25 |
| Change, 1 year | −19.7% | −52.6% |
| Change, 5 years | −79.3% | −89.1% |
| Beta (5Y) | 1.56 | 0.85 |
| Employees | 2,700 | 6,500 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 3 | 3 |
| Growth score | 0 | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× | 0.3× (better) |
| P/B | 2.0× | 0.5× (better) |
| FCF yield | – | −23.2% |
| Fair value | $18.75 | $84.25 |
| Margin of safety | 66.1% | 84.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −3.2% | −2.5% (better) |
| Revenue growth, 5Y average | −0.63% | 10.4% (better) |
| Profitability | ||
| Gross margin | 68.8% (better) | 44.6% |
| Operating margin | −12.2% (better) | −30.8% |
| Net margin | −14.0% (better) | −39.2% |
| FCF margin | – | −7.9% |
| Return on equity | −32.5% (better) | −45.9% |
| Return on invested capital | −22.8% | −13.3% (better) |
| Financial health | ||
| Debt / equity | 0.40 (better) | 1.63 |
| Interest coverage | −6.0× | −4.1× (better) |
| Current ratio | 2.21 (better) | 1.39 |
| Altman Z-score | −0.49 | −0.08 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.57% |
| Shareholder yield | 0.00% (better) | −0.57% |
| Ownership | ||
| Held by institutions | 94.1% | 121% |
| Held by insiders | 7.2% | 43.4% |
| Insider net buying, 12 months | $655K | $1.2M (better) |
| Short interest, % of float | 9.6% | 38.5% |
Go deeper
- MYGN stock overview
- MYGN income statement
- MYGN valuation and score
- QDEL stock overview
- QDEL income statement
- QDEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.